Literature DB >> 20009903

Preventing cervical cancer: stakeholder attitudes toward CareHPV-focused screening programs in Roi-et Province, Thailand.

Lee A Trope1, Bandit Chumworathayi, Paul D Blumenthal.   

Abstract

OBJECTIVE: To assess which of the 5 CareHPV-inclusive protocols stakeholders in Roi-et Province, Thailand found (1) most preferable and (2) most beneficial to the overall goal of reducing cervical cancer.
DESIGN: Five CareHPV-inclusive cancer prevention approaches were presented to a convenience sample of colposcopists, trainers, health care providers, district medical directors, and district health officers. Participants ranked their preference for each plan (A-E) compared with the current screening protocol and also the perceived comparative benefit of the plans. Plans differed in whether every patient was screened using both the human papillomavirus (HPV) test and visual inspection with acetic acid (VIA) or only HPV-positive women were screened with VIA; in clinician versus self-swab and in hospital/clinic-based or village-based screening.
RESULTS: Overall, participants supported an innovative plan in which women would be screened in their homes and villages using the self-swab version of the CareHPV DNA test, and only those who screened positive for HPV are screened with VIA. When results were stratified by provider type (physician vs nonphysician) and/or practice concentration (hospital-oriented vs field-oriented), preference and perceived benefit for the plans differed significantly with physician/hospital-oriented participants and are more likely to be skeptical of the self-swab version of the CareHPV test.
CONCLUSIONS: Providers in Thailand recognize the potential value of a rapid HPV test as part of a cervical cancer prevention program and, overall, support a patient-administered self-swab followed by visual confirmation and treatment as the most practical CareHPV-inclusive approach largely because of the likely increase in coverage. Future studies will further define the clinical benefits and limitations of this test.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20009903     DOI: 10.1111/IGC.0b013e3181a83dd0

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  3 in total

1.  Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in Zambia.

Authors:  Mulindi H Mwanahamuntu; Vikrant V Sahasrabuddhe; Sharon Kapambwe; Krista S Pfaendler; Carla Chibwesha; Gracilia Mkumba; Victor Mudenda; Michael L Hicks; Sten H Vermund; Jeffrey S A Stringer; Groesbeck P Parham
Journal:  PLoS Med       Date:  2011-05-17       Impact factor: 11.069

2.  Demographic, knowledge, attitudinal, and accessibility factors associated with uptake of cervical cancer screening among women in a rural district of Tanzania: three public policy implications.

Authors:  Frida S Lyimo; Tanya N Beran
Journal:  BMC Public Health       Date:  2012-01-10       Impact factor: 3.295

3.  Low-cost HPV testing and the prevalence of cervical infection in asymptomatic populations in Guatemala.

Authors:  Hong Lou; Eduardo Gharzouzi; Sarita Polo Guerra; Joël Fokom Domgue; Julie Sawitzke; Guillermo Villagran; Lisa Garland; Joseph F Boland; Sarah Wagner; Héctor Rosas; Jami Troxler; Heidi McMillen; Bailey Kessing; Enrique Alvirez; Miriam Castillo; Hesler Morales; Victor Argueta; Andert Rosingh; Femke J H B van Aerde-van Nunen; Griselda Lopez; Herbert M Pinedo; Mark Schiffman; Michael Dean; Roberto Orozco
Journal:  BMC Cancer       Date:  2018-05-15       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.